Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2026 Earnings Call Transcript May 5, 2026Adaptive Biotechnologies Corporation beats earnings expectations.
Adaptive Biotechnologies Corp (ADPT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 29,993,708 | $416,312,667 | 1.16% | |
| 2. | ARK Investment Management Catherine D. Wood | 2,092,969 | $29,050,406 | -3% | 0.23% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,995,202 | $27,693,404 | -18% | 0.01% |
| 4. | D E Shaw D. E. Shaw | 1,965,610 | $27,282,666 | +4% | 0.02% |
| 5. | Driehaus Capital Richard Driehaus | 1,750,601 | $24,298,342 | -37% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 2,500 | $50,000.00 | 2,500 | 2019-07-01 | Filing | |
| $20.00 | 1,000 | $20,000.00 | 1,000 | 2019-07-01 | Filing | |
| $20.00 | 300 | $6,000.00 | 300 | 2019-07-01 | Filing | |
| $20.00 | 400 | $8,000.00 | 400 | 2019-07-01 | Filing | |
| $20.00 | 500 | $10,000.00 | 500 | 2019-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.23 | 19,037 | $270,896.51 | 377,802 | 2026-04-27 | Filing | |
| $14.02 | 19,060 | $267,221.20 | 382,132 | 2026-04-24 | Filing | |
| $13.74 | 19,060 | $261,884.40 | 386,470 | 2026-04-23 | Filing | |
| $14.13 | 19,060 | $269,317.80 | 390,808 | 2026-04-22 | Filing | |
| $14.66 | 30,941 | $453,595.06 | 395,146 | 2026-04-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,303,025 | $184,645,993 | 0% | |
| 2. | 6,094,144 | $84,586,719 | 0% | |
| 3. | 5,436,718 | $75,461,646 | 0.32% | |
| 4. | 4,491,474 | $62,341,659 | 0% | |
| 5. | 4,450,066 | $61,766,916 | 0.01% |
News See All
Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best hot stocks under $20 to buy.
10 Hot Stocks Under $20 to Buy
On February 24, Luke Barrs, Goldman Sachs Asset Management chief business and client officer for fundamental equities, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends and ...
TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)
On February 6, 2026, TD Cowen upgraded Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price target to $21 from $20 while keeping a Buy rating, citing a Q4 beat and an improved outlook.
11 Most Volatile Stocks to Buy According to Hedge Funds
On February 17, 2026, Bloomberg reported that stocks fluctuated significantly as investors assessed the risks of artificial intelligence. The S&P 500 climbed 0.1%, while a software ETF sank 2.2%.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript February 5, 2026Adaptive Biotechnologies Corporation beats earnings expectations.
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake
In separate regulatory filings last week, Adaptive Biotechnologies Corp.
Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why
Among others, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) said it expects its pharmaceutical services to generate $20 million in revenues, and anticipates EMR integrated testing volumes to exceed...
Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and...
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Third Quarter Earnings Conference Call.
Hedge Fund Resource Center